Portal de Periódicos da CAPES

Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score

2017; Elsevier BV; Volume: 51; Issue: 3 Linguagem: Inglês

10.1016/j.ijantimicag.2017.09.010

1872-7913

Javier Cobo, Esperanza Merino, Cristina Martínez, Alberto Cózar-Llistó, Evelyn Shaw, Teresa Marrodán, Esther Calbo, Elena Bereciartúa, Luis Ángel Sánchez-Muñoz, Miguel Salavert, Pérez Rodríguez, Dácil García-Rosado, José María Bravo-Ferrer, Juan Gálvez-Acebal, César Henríquez-Camacho, Jordi Cuquet, Berta Pino-Calm, Luis Carlos Domínguez, Antonio Sánchez-Porto, Borja M. Fernández-Félix, J. Romero, Alfonso Muriel, Livia Giner, Vicente Boix, António Ramos, Rocío Martínez, Purificación Martos, Olga Arch, Cristina Sardiña, Elena Aguirre, Cristina Badía, Lucía Boix-Palop, Ildefonso Perales, Pedro Ángel de Santos-Castro, Miguel Ángel Bratos-Pérez, Sandra Cuéllar, Eva López González, Adriana Soto, Adrián Sousa, Pedro Llinares, Laura Castelo, Isabel Morales, Jesús Fernández‐Sojo, Alberto Delgado‐Iribarren, Carmina Martí, Rosa Maria Vazquez, Pilar Mairal,

Helicobacter pylori-related gastroenterology studies

Recurrence of Clostridium difficile infection (CDI) has major consequences for both patients and the health system. The ability to predict which patients are at increased risk of recurrent CDI makes it possible to select candidates for treatment with new drugs and therapies (including fecal microbiota transplantation) that have proven to reduce the incidence of recurrence of CDI. Our objective was to develop a clinical prediction tool, the GEIH-CDI score, to determine the risk of recurrence of CDI. Predictors of recurrence of CDI were investigated using logistic regression in a prospective cohort of 274 patients diagnosed with CDI. The model was calibrated using the Hosmer-Lemeshow test. The tool comprises four factors: age (70–79 years and ≥80 years), history of CDI during the previous year, direct detection of toxin in stool, and persistence of diarrhea on the fifth day of treatment. The functioning of the GEIH-CDI score was validated in a prospective cohort of 183 patients. The area under the ROC curve was 0.72 (0.65–0.79). Application of the tool makes it possible to select patients at high risk (>50%) of recurrence and patients at low risk (<10%) of recurrence. GEIH-CDI score may be useful for clinicians treating patients with CDI.